Doravirine: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Doravirine. Educational only — not medical advice.
Labeled uses
DELSTRIGO® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history, OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO [see Clinical Studies (14) ] .
Source: FDA labeling via NIH DailyMed (set cd1e9f84…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.